Price worries and bureaucratic obstacles have slowed uptake of the drug. This is a KFF Health News story. Evangelical minister Eddie Hyatt believes in the healing power of prayer but "also the medical ...

Advisers to the US Food and Drug Administration voted 16-1 on Thursday in support of full approval of Paxlovid, stating that the benefits outweigh the risks of the drug for treatment of mild to ...

The COVID pill from Pfizer is still available for children ages 12 to 17 under a separate emergency authorization WASHINGTON (AP) — Pfizer received full approval on Thursday for its COVID-19 pill ...

FILE - The anti-viral drug Paxlovid is displayed in New York, Monday, Aug. 1, 2022. Pfizer received full approval for the COVID-19 medication on Thursday, May 25, 2023, winning the U.S. Food and Drug ...

Americans with COVID-19 have been taking Paxlovid since it was approved under emergency use in late 2021. Today, the U.S. Food and Drug Administration granted full approval to the drug. This approval ...

Credit: Pfizer. The is the first approval of an oral antiviral therapy for COVID-19. The Food and Drug Administration (FDA) has approved Paxlovid (nirmatrelvir tablets and ritonavir tablets, ...

Pfizer’s Paxlovid now has full FDA approval for treating mild-to-moderate Covid-19, a regulatory decision that makes the pill the first oral antiviral for the novel coronavirus. The approval announced ...

The Biden administration will continue to manage the distribution of free courses of Pfizer's Paxlovid treatment for COVID-19 for at least another few months, the drugmaker said, even after the Food ...

(CNN) — The US Food and Drug Administration on Thursday fully approved the antiviral medication Paxlovid to treat mild to moderate Covid-19 in adults at risk of severe infections. Paxlovid had been ...

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to sell it on the commercial market later this year. A company spokesperson on Wednesday ...

Price worries, bureaucratic obstacles, and “I’m-over-COVID-itis” are slowing uptake of Paxlovid, a drug that’s complicated to take but often effective. Since late December, when Pfizer shifted to ...